Claims
- 1. Method for screening for endometriosis, comprising the steps of:
- a) originating with a female human a saliva sample;
- b) providing an anthocyanin 3,5-diglucoside pigment at a concentration of between about 8.times.10.sup.-5 M and 1.times.10.sup.-3 M at a pH of between about 5.0 and 7.5 responsive to the capacity of the saliva sample to change its free estrogen solubility level;
- c) contacting the pigment with the saliva sample and permitting a color response to occur; and
- d) detecting from the color response of the pigment whether there are imbalances in how the saliva sample responds to changes in its capacity to absorb free estrogen and thereby screening for endometriosis.
- 2. Method of claim 1, wherein detecting the color response through one of visual perception, optical density determination, and chromatography.
- 3. Method of claim 2, including the step of:
- a) providing a color chart having at least two preselected colors, one color indicative of whether the saliva sample has achieved its maximal capacity to absorb free estrogen; and
- b) evaluating the color response of the pigment by comparison with the color chart.
- 4. Method of claim 3, wherein the anthocyanin pigment is selected so as to generate a blue color response to the saliva sample having achieved maximum capacity to absorb free estrogen.
- 5. Method of claim 2, wherein the color response is detectd by optical measurement, the optical density determination being performed between 500 nm and 620 nm.
- 6. Method of claim 1, wherein the pigment on the substrate is at a concentration between about 5.times.10.sup.-5 M to 1.times.10.sup.-3 M.
- 7. Method of claim 1, wherein the saliva sample is at a temperature of less than 100.degree. F.
- 8. Method of claim 1, including the steps of:
- adding a known amount of extrogen to the saliva sample after step 6; and
- repeating step c in order to determine how much of said estrogen must be added to the saliva sample in order to determine the maximum sensitivity for estrogen absorption of the saliva sample.
- 9. Method of claim 8, wherein the estrogen is estradiol.
- 10. Method of claim 8, wherein the estrogen is 17 beta estradiol.
- 11. Method of claim 1, wherein the pigment is malvidin 3,5 diglucoside, petunidin 3,5 diglucoside, cyanidin 3,5 diglucoside, or pelegordinin 3,5 diglucoside.
- 12. Method of claim 1, wherein the pigment has the following general formula: ##STR4## wherein R.sub.1 is selected from the group consisting of hydrogen, hydroxy, and C.sub.1 -C.sub.4 alkoxy; R.sub.2 is selected from the group consisting of hydrogen, hydroxy, and C.sub.1 -C.sub.4 alkoxy; R.sub.3 is a glycoside selected from the group consisting of glucosides, rutinosides, arabinosides, sophorosides, p-cuomaroyl, rutinosides, and rhamnosides; and R.sub.5 is a glycoside selected from the group consisting of glucosides, and X.sup.+ is a cation.
- 13. Method of claim 1, wherein a substrate is provided allowing solid phase contact between the saliva sample and the pigment and the substrate is formed from a material selected from the group consisting of transparent glass strip, acetate, polyethylene, acrylic, and cellulose.
- 14. Method of claim 1, wherein components having a size in excess of 10,000 Daltons are filtered from the saliva sample prior to contact with the pigment.
- 15. Method of claim 14, wherein the filtering of the saliva sample is performed using a wick formed from the group consisting of cotton, cellulose, absorbent materials, and molecular sieves.
- 16. Method of claim 1, wherein applying a metal salt with the pigment prior to contacting the pigment with the saliva sample.
- 17. Method of claim 16, wherein the metal salt is calcium chloride.
- 18. The method of claim 1, further comprising the step of:
- e) repeating steps b through d of claim 1 with a plurality of saliva samples taken over a selected time interval.
- 19. The method of claim 18, wherein the saliva samples are taken over a period of at least five days, with at least one sample being taken each day.
- 20. The method of claim 19, further including the step of:
- f) recording each color response.
- 21. Method for indicating parturition, comprising the steps of:
- a) originating with a female mammal a saliva sample;
- b) providing an anthocyanin 3,5 diglucoside pigment at a concentration of from about 8.times.10.sup.-5 M to about 1.times.10.sup.-3 M at a pH of between 5.0 and 7.5 responsive to the capacity of the saliva sample to change its free estrogen solubility level;
- c) contacting the pigment with the saliva sample and permitting a color response to occur; and
- d) detecting from the color response of the pigment whether the body fluid has achieved its capacity to absorb free estrogen and thereby screening for an indication that parturition may be imminent.
- 22. Method for indicating synchrony during embryo implantation, comprising the steps of:
- a) originating a plurality of saliva samples, each sample taken from a different female mammal;
- b) contacting each saliva sample with an anthocyanin 3,5 diglucoside pigment at a concentration of from about 8.times.10.sup.-5 M to about 1.times.10.sup.-3 M at a pH of between 5.0 and 7.5 responsive to the capacity of the saliva samples to change their free estrogen solubility levels so that a color response occurs; and
- c) evaluating the color response of each saliva sample that has been contacted with the anthocyanin pigment and thereby monitoring for synchrony in color responses between at least two of the female mammals.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a rule 371 national phase filing of PCT application No. PCT/US96/04007, which was a continuation-in-part of my then co-pending U.S. patent application Ser. No. 08/408,966, filed Mar. 23, 1995 now abandoned and application Ser. No. 08/855,590, filed May 13, 1997.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/US96/04007 |
3/25/1996 |
|
|
9/22/1997 |
9/22/1997 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO96/29606 |
9/26/1996 |
|
|
US Referenced Citations (5)
Non-Patent Literature Citations (1)
Entry |
Markaverich. B.M. et al, "Bioflavonoid Interaction With Rat Uterine Type II Binding Sites and Cell Growth Inhibition," J. Steriod Biochem 30(1-6):71-78, 1988. |
Related Publications (1)
|
Number |
Date |
Country |
|
855590 |
May 1997 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
408966 |
Mar 1995 |
|